By stably binding to AMPK1, SYK, and RAC1, these components may inhibit the activation and migration of inflammatory cells and reduce the release of inflammatory mediators, thereby alleviating the symptoms of allergic rhinitis. This evidence concerns the gene PRKAA1 and allergic rhinitis.